Outcomes of Neoadjuvant Chemotherapy for Clinical Stages 2 and 3 Gastric Cancer Patients: Analysis of Timing and Site of Recurrence

ConclusionsThe majority of the recurrences for patients with clinical stage 2 or 3 gastric cancer who received neoadjuvant chemotherapy and underwent curative resection occurred within 2 years. After neoadjuvant chemotherapy, pathologic T stage was a useful risk predictor for early recurrence.

http://link.springer.com/10.1245/s10434-021-09624-5

Source: Annals of Surgical Oncology - February 10, 2021 Category: Cancer & Oncology Source Type: research